Literature DB >> 34220036

Model-free estimates that complement information obtained from the hazard ratio.

Salil Vasudeo Deo1,2, Vaishali Salil Deo1, Varun Sundaram1,2.   

Abstract

Understand the limitations of the modeling of survival data, especially as pertains to the Cox proportional hazards model.An introduction to model-free estimates of survival, namely, the restricted mean survival time/restricted mean lost time.Use R (The R Foundation for Statistical Computing, Austria) or STATA® (The STATACorp, College Station, TX, USA) to perform analyses and obtain these parameters from a dataset. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12055-021-01167-4. © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021.

Entities:  

Keywords:  Biostatistics; Kaplan and Meier method; Median survival time; Restricted mean survival time; Survival analysis

Year:  2021        PMID: 34220036      PMCID: PMC8218107          DOI: 10.1007/s12055-021-01167-4

Source DB:  PubMed          Journal:  Indian J Thorac Cardiovasc Surg        ISSN: 0970-9134


  9 in total

1.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

Authors:  Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

2.  The estimation of average hazard ratios by weighted Cox regression.

Authors:  Michael Schemper; Samo Wakounig; Georg Heinze
Journal:  Stat Med       Date:  2009-08-30       Impact factor: 2.373

3.  Treatment of lung cancer.

Authors:  Enzo Ballatori; Sonia Fatigoni; Fausto Roila
Journal:  N Engl J Med       Date:  2009-12-17       Impact factor: 91.245

4.  The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  Stat Med       Date:  2011-05-25       Impact factor: 2.373

5.  Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.

Authors:  Hajime Uno; Brian Claggett; Lu Tian; Eisuke Inoue; Paul Gallo; Toshio Miyata; Deborah Schrag; Masahiro Takeuchi; Yoshiaki Uyama; Lihui Zhao; Hicham Skali; Scott Solomon; Susanna Jacobus; Michael Hughes; Milton Packer; Lee-Jen Wei
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

6.  Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes.

Authors:  David E Kloecker; Melanie J Davies; Kamlesh Khunti; Francesco Zaccardi
Journal:  Ann Intern Med       Date:  2020-03-24       Impact factor: 25.391

Review 7.  Survival analysis and regression models.

Authors:  Brandon George; Samantha Seals; Inmaculada Aban
Journal:  J Nucl Cardiol       Date:  2014-05-09       Impact factor: 5.952

8.  Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease.

Authors:  Gregg W Stone; A Pieter Kappetein; Joseph F Sabik; Stuart J Pocock; Marie-Claude Morice; John Puskas; David E Kandzari; Dimitri Karmpaliotis; W Morris Brown; Nicholas J Lembo; Adrian Banning; Béla Merkely; Ferenc Horkay; Piet W Boonstra; Ad J van Boven; Imre Ungi; Gabor Bogáts; Samer Mansour; Nicolas Noiseux; Manel Sabaté; Jose Pomar; Mark Hickey; Anthony Gershlick; Pawel E Buszman; Andrzej Bochenek; Erick Schampaert; Pierre Pagé; Rodrigo Modolo; John Gregson; Charles A Simonton; Roxana Mehran; Ioanna Kosmidou; Philippe Généreux; Aaron Crowley; Ovidiu Dressler; Patrick W Serruys
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

9.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.